Description

Expanded analysis of melatonin receptor expression (MT1/MT2) across prostate cancer cell lines, establishing the receptor-dependent mechanism of MLT action.

Figure 34

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 34: Expanded analysis of melatonin receptor expression (MT1/MT2) across prostate cancer cell lines, establishing the receptor-dependent mechanism of MLT action.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Expanded analysis of melatonin receptor expression (MT1/MT2) across prostate cancer cell lines, establishing the receptor-dependent mechanism of MLT action." />
  <figcaption>Figure 34. Expanded analysis of melatonin receptor expression (MT1/MT2) across prostate cancer cell lines, establishing the receptor-dependent mechanism of MLT action.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

Related Evidence

Melatonin for Circadian Rhythm Disorder

Grade A · 176 studies